Criterios de inclusión: - Los pacientes deben poder proporcionar un formulario de consentimiento informado (ICF) por escrito - Deben estar dispuestos y ser capaces de completar instrumentos de Calidad de vida relacionada con la salud (Health-related quality of life, HRQoL) iniciales y de seguimiento, para los cuales los pacientes deben ser competentes en inglés o español - Los pacientes con LMA deben tener al menos 55 años de edad al momento del consentimiento informado. - Los pacientes con MF, ICUS y SMD deben tener al menos 18 años de edad al momento del consentimiento informado . Citopenias idiopáticas de significado incierto (ICUS) de diagnóstico reciente, síndromes mielodisplásicos (SMD), pacientes con leucemia mieloide aguda (LMA): - Enfermedad primaria o secundaria de diagnóstico reciente. Para ser considerado "newly diagnosed", a patient's confirmed diagnosis must be made no more than 60 days prior to the date of consent signature. (An additional 5-day window [i.e., up to 65 days prior to the date of ICF signature] may be allowed in special circumstance upon sponsor approval) - Cohort assignment confirmed by central eligibility review. Cohort assignment must also be confirmed by the site. Myelofibrosis (MF) patients: - Patients who initiated their first active systemic treatment for MF and/or MF-related cytopenias within 90 days prior to the date of consent signature. This cohort allows the enrollment of subjects with a diagnosis of Myelodysplastic/Myeloproliferative overlap syndromes (MDS/MPN overlap syndrome). - Cohort assignment is confirmed by the site. Central eligibility review is not required. Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS) patients: - Patients who have initiated first active treatment regimen containing at least one non-ESA therapy, within 90 days prior to ICF - Cohort assignment is confirmed by site. Central eligibility review is not required. Exclusion Criteria: - Suspected or proven acute promyelocytic leukemia (APL) (FAB M3 or WHO 2008) based on morphology, immunophenotype, molecular assay or karyotype - Currently enrolled in any interventional clinical trial where the patient is being treated with an investigational product that cannot be identified. - Idiopathic Cytopenias of Undetermined Significance (ICUS), Myelodysplastic Syndromes (MDS) patients who received or are receiving active (disease modifying) therapy for the treatment of MDS prior to the date of informed consent. - Acute Myeloid Leukemia (AML) patients who initiated active (disease modifying treatment for AML more than 2 weeks prior to the date of consent. - Myelofibrosis (MF) and Myelodysplastic/Myeloproliferative (MDS/MPN) overlap syndrome patients with suspected juvenile myelomonocytic leukemia (JMML).